Kiniksa Pharmaceuticals International PLC (NAS:KNSA)
$ 22.32 0.28 (1.27%) Market Cap: 1.61 Bil Enterprise Value: 1.40 Bil PE Ratio: 0 PB Ratio: 3.69 GF Score: 58/100

Kiniksa Pharmaceuticals Ltd at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 16, 2020 / 06:00PM GMT
Release Date Price: $17.14 (-1.15%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Good afternoon, and welcome, once again, to the Morgan Stanley 18th Annual Global Healthcare Conference. I'm one of the biotech analysts from Morgan Stanley. My name is David Lebowitz.

Before we get started, we'd run through the requisite disclosures. Please note that this webcast is for Morgan Stanley clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

And with that, I'm happy to introduce today, I have with me Kiniksa Pharmaceuticals. And I guess if they could start out, give a brief introduction to themselves. Start with -- I guess hand it off to CEO, Sanj Patel, to his team, provide a top-level

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot